Company C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for C4 Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:14:31 2023-12-05 am EST			5-day change	1st Jan Change
1.515 ^USD	-2.26%		-2.59%	-74.08%

Nov. 20	C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	CI
Nov. 07	North American Morning Briefing : Higher Bond -2-	DJ

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Number of employees : 146

USD in Million	2021	Weight	2022	Weight	Delta
Biogen License 61.8 %	16	34.3 %	19	61.8 %	+22.23%
Calico License 22.3 %	11	23.3 %	7	22.3 %	-35.03%
Restated Roche 15.9 %	19	42.3 %	5	15.9 %	-74.51%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	46	100.0 %	31	100.0 %	-32.08%

Managers	Title	Age	Since
Andrew Hirsch CEO	Chief Executive Officer	52	2020
Kendra Adams DFI	Director of Finance/CFO	47	2020
Mayra Reyes-Armour CTO	Chief Tech/Sci/R&D Officer	-	2020
Stewart Fisher CTO	Chief Tech/Sci/R&D Officer	56	2016
Scott Boyle PRN	Corporate Officer/Principal	45	-
Jolie Siegel LAW	General Counsel	46	2020
M. Isabel Chiu PRN	Corporate Officer/Principal	-	2016
Kelly Schick HRO	Human Resources Officer	43	2021
Bihua Chen PRN	Corporate Officer/Principal	55	2015

Members of the board	Title	Age	Since
Bruce Downey CHM	Chairman	75	2015
Glenn Dubin BRD	Director/Board Member	66	2021
Bihua Chen PRN	Corporate Officer/Principal	55	2015
Donna Grogan BRD	Director/Board Member	66	2022
Kenneth Anderson FOU	Founder	71	2015
Andrew Hirsch CEO	Chief Executive Officer	52	2020
Malcolm Salter BRD	Director/Board Member	83	2015
Utpal Koppikar BRD	Director/Board Member	52	2022
Laura Bessen BRD	Director/Board Member	60	2022

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,281,046	45,376,460 ( 92.08 %)	0	92.08 %

Name	Equities	%	Valuation
Wasatch Advisors, Inc. 8.504 %	4,183,051	8.504 %	6 M $
RTW Investments LP 5.732 %	2,819,472	5.732 %	4 M $
Aquilo Capital Management LLC 4.046 %	1,990,334	4.046 %	3 M $
Cohen Marc A /Estate Of/ 4.016 %	1,975,381	4.016 %	3 M $
The Vanguard Group, Inc. 3.913 %	1,924,856	3.913 %	3 M $
T. Rowe Price Associates, Inc. (Investment Management) 3.700 %	1,820,216	3.700 %	3 M $
Bain Capital Life Sciences LP 3.338 %	1,642,210	3.338 %	2 M $
TCG Crossover Management LLC 2.595 %	1,276,574	2.595 %	2 M $
Millennium Management LLC 2.373 %	1,167,372	2.373 %	2 M $
ArrowMark Colorado Holdings LLC 2.353 %	1,157,606	2.353 %	2 M $

C4 Therapeutics, Inc.

675 West Kendall Street

02142, Cambridge

http://www.c4therapeutics.com

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.55USD

Average target price

16.2USD

Spread / Average Target

+945.16%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
C4 THERAPEUTICS, INC.	-74.08%	76 M $
SEAGEN INC.	+65.85%	40 210 M $
IQVIA HOLDINGS INC.	+4.48%	39 469 M $
MODERNA, INC.	-56.37%	30 453 M $
LONZA GROUP AG	-26.20%	28 080 M $
ICON PUBLIC LIMITED COMPANY	+37.33%	21 949 M $
ALNYLAM PHARMACEUTICALS, INC.	-27.93%	21 694 M $
CELLTRION, INC.	+1.31%	17 245 M $
UNITED THERAPEUTICS CORPORATION	-14.54%	11 276 M $
BIO-TECHNE CORPORATION	-21.89%	10 327 M $

Other Biotechnology & Medical Research